Abbott India ups vaccines play, to launch products in infant segment

Abbott India Ltd (AIL), the listed subsidiary of US-based Abbott Laboratories and a new entrant in the Indian vaccines market, has seen good traction and plans to bring in new products in the toddler and infant vaccines segment. The company may go for tie-ups to bring in new products. 

According to analysts, AIL’s presence in the high-margin vaccine segment is likely to drive its future growth. The Indian vaccine market (valued at $250 million) is expected to grow to $1.7 billion by 2020 and is led by multinationals like GlaxoSmithKline (28 per cent market share) and Sanofi (17 per cent market